Why Wave Life Sciences Stock Crushed it Again Today

The nearly 150% price pop Wave Life Sciences (NASDAQ: WVE) stock experienced on Monday was a hard act to follow. But the biotech's shares continued to be a hot item the following day, although that session's gain was "only" 15%. Investors continued to load up on the stock after an analyst's recommendation upgrade and several pundit price target raises. Wave's bullish start to the week was driven by the encouraging readout of a Phase 1 clinical study of WVE-007, its obesity drug candidate. Weight-loss drugs are all the rage these days in the U.S., which has many overweight people living within its borders. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool